Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 5 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Cabozantinib for Hepatocellular Carcinoma Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Cabozantinib for treating differentiated thyroid cancer Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Differentiated thyroid cancer (DTC) Head and Neck Cancer 2021 View  |  Download
Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Nivolumab in combination with cabozantinib for metastatic renal cell carcinoma – first-line Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Renal cell carcinoma (RCC) Renal Cancer 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications